Compare Abeona Therapeutics Inc (ABEO) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VanEck Vietnam ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while VanEck Vietnam ETF trades at $18.27. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | VNM | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $19.80 |
52-Week Low | $4.17 | $14.51 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VNM trades at $18.19, down 1.62% on the day, with technical indicators signaling a bearish trend. The stock faces selling pressure from moving averages and oscillators, while support and resistance cluster around $18. Recent news highlights underperformance relative to emerging markets and global equities, compounded by Vietnam-specific risks like power grid strain from heatwaves.
The outlook remains cautious due to weak technical momentum and external headwinds. Investment opportunities hinge on Vietnam's economic resilience and potential foreign inflows from FTSE Russell's reclassification. Key risks include geopolitical tensions, climate impacts on infrastructure, and sustained underperformance versus peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
